- $7.72bn
- $9.28bn
- $2.76bn
- 51
- 17
- 19
- 18
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.22 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 261.4 | ||
| Price to Sales | 2.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -19.99% | ||
| Return on Equity | -37.09% | ||
| Operating Margin | -37.64% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,491.39 | 1,767.09 | 2,084.28 | 2,499.77 | 2,758.87 | 3,055.18 | 3,452.25 | 25.78% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Directors
- Kevin Conroy CHM (55)
- Jeffrey Elliott CFO (43)
- D. Scott Coward SVP (56)
- Ana Hooker SVP (54)
- Graham Lidgard CSO
- Jake Orville GMG (47)
- Gisela Paulsen GMG (55)
- James Doyle IND (75)
- Pierre Jacquet IND (54)
- Daniel Levangie IND (70)
- Freda Lewis-Hall IND (66)
- Shacey Petrovic IND (47)
- Kathleen Sebelius IND (73)
- Katherine Zanotti IND (66)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 10th, 1995
- Public Since
- January 30th, 2001
- No. of Shareholders
- 172
- No. of Employees
- 6,900
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 185,755,406
- Address
- 5505 Endeavor Lane, MADISON, 53719
- Web
- https://www.exactsciences.com/
- Phone
- +1 6082845700
- Auditors
- PricewaterhouseCoopers LLP
Latest News for EXAS
Upcoming Events for EXAS
Q1 2025 Exact Sciences Corp Earnings Release
Q1 2025 Exact Sciences Corp Earnings Call
Exact Sciences Corp Annual Shareholders Meeting
Q2 2025 Exact Sciences Corp Earnings Release
Similar to EXAS
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 20:33 UTC, shares in Exact Sciences are trading at $41.58. This share price information is delayed by 15 minutes.
Shares in Exact Sciences last closed at $41.58 and the price had moved by -34.23% over the past 365 days. In terms of relative price strength the Exact Sciences share price has underperformed the S&P500 Index by -38.16% over the past year.
The overall consensus recommendation for Exact Sciences is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreExact Sciences does not currently pay a dividend.
Exact Sciences does not currently pay a dividend.
Exact Sciences does not currently pay a dividend.
To buy shares in Exact Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $41.58, shares in Exact Sciences had a market capitalisation of $7.72bn.
Here are the trading details for Exact Sciences:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: EXAS
Based on an overall assessment of its quality, value and momentum Exact Sciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Exact Sciences is $67.37. That is 62.03% above the last closing price of $41.58.
Analysts covering Exact Sciences currently have a consensus Earnings Per Share (EPS) forecast of -$0.47 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Exact Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -35.94%.
As of the last closing price of $41.58, shares in Exact Sciences were trading -25.45% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Exact Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $41.58.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Exact Sciences' management team is headed by:
- Kevin Conroy - CHM
- Jeffrey Elliott - CFO
- D. Scott Coward - SVP
- Ana Hooker - SVP
- Graham Lidgard - CSO
- Jake Orville - GMG
- Gisela Paulsen - GMG
- James Doyle - IND
- Pierre Jacquet - IND
- Daniel Levangie - IND
- Freda Lewis-Hall - IND
- Shacey Petrovic - IND
- Kathleen Sebelius - IND
- Katherine Zanotti - IND